Conditions: High Blood Pressure Metabolic Syndrome Insulin Resistance Endothelial Dysfunction
Keywords: High Blood pressure Hypertension metabolic syndrome insulin resistance endothelial dysfunction pre-diabetic amlodipine, aliskiren, IGT, IFG, MBF
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 48
Healthy volunteers: no

Brief summary:
The purpose of this study was to determine the effects of Aliskiren on insulin resistance (IR) and endothelial dysfunction (ED) in patients with high blood pressure and metabolic syndrome. The efficacy of Aliskiren was compared to Amlodipine.

Detailed description:

Arms:
arm 1: Eligible participants received oral Aliskiren 300 mg + Placebo Amlodipine once daily for 12 weeks. Study medication was taken with 200 mL of water in the morning. Breakfast was eaten 1 hour after taking study medication. Study medication was swallowed whole, and not chewed. arm 2: Eligible participants received oral Amlodipine 5 mg + Placebo Aliskiren once daily for 12 weeks. Study medication was taken with 200 mL of water in the morning. Breakfast was eaten 1 hour after taking study medication. Study medication was swallowed whole, and not chewed.

Interventions: intervention 1: Aliskiren intervention 2: Amlodipine intervention 3: Placebo Aliskiren intervention 4: Placebo Amlodipine
Intervention descriptions: intervention 1: Aliskiren 300 mg tablets taken orally once daily intervention 2: Amlodipine 5 mg capsule taken orally once daily intervention 3: Placebo Aliskiren taken orally once daily. intervention 4: Placebo Amlodipine taken orally once daily

Protocol document: